Journal article
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
The New England journal of medicine, Vol.375(22), pp.2144-2153
12/01/2016
DOI: 10.1056/NEJMoa1604304
PMID: 27959767
Abstract
Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown.
We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes.
Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes.
In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive. (Funded by the Medical Research Council and the National Heart, Lung, and Blood Institute.).
Details
- Title: Subtitle
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- Creators
- Brian A Ference - Wayne State UniversityJennifer G Robinson - University of IowaRobert D Brook - University of Michigan–Ann ArborAlberico L Catapano - University of MilanM John Chapman - InsermDavid R Neff - Michigan State UniversitySzilard VorosRobert P Giugliano - Harvard Medical SchoolGeorge Davey Smith - University of BristolSergio Fazio - Oregon Health and Science University HospitalMarc S Sabatine - Harvard Medical School
- Resource Type
- Journal article
- Publication Details
- The New England journal of medicine, Vol.375(22), pp.2144-2153
- Publisher
- United States
- DOI
- 10.1056/NEJMoa1604304
- PMID
- 27959767
- ISSN
- 1533-4406
- eISSN
- 1533-4406
- Grant note
- MC_UU_12013/1 / Medical Research Council
- Language
- English
- Date published
- 12/01/2016
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983996189302771
Metrics
37 Record Views